BURLINGTON, Mass., Sept. 19, 2014 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT ), a provider of peripheral vascular devices and implants, announced today that on September 17, 2014 it acquired the angioscope product line from Applied Medical, Inc. for $420,000. Last 12 months' sales of the device are estimated to be $360,000. Angioscopes are fiberoptic catheters that allow visualization of the interior of peripheral arteries and veins. They are commonly used to assess vein quality or confirm valve lysis during peripheral bypass, the procedure in which the HYDRO LeMaitre Valvulotome is used.
"This tuck-in acquisition adds to our sales bag a valuable diagnostic tool that complements our #1 product line," said David Roberts, President of LeMaitre Vascular. "We anticipate a smooth integration."
In conjunction with the acquisition, Applied Medical will provide manufacturing transition services from its production facility in Orange County, CA for up to one year.
Business Outlook
Guidance on how this acquisition may affect LeMaitre Vascular's 2014 revenue and operating income will be provided at the Company's Q3 2014 earnings call.
About LeMaitre Vascular
LeMaitre Vascular is a provider of devices for the treatment of peripheral vascular disease, a condition that affects more than 20 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon.
LeMaitre and the LeMaitre Vascular logo are registered trademarks of LeMaitre Vascular, Inc. This press release contains other trademarks and trade names of the Company.
For more information about the Company, please visit http://www.lemaitre.com .
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this press release regarding the Company's business that are not historical facts may be "forward-looking statements" that involve risks and uncertainties. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties that could cause actual results to differ from the results predicted. These risks and uncertainties include, but are not limited to, the risk that the Company may not realize the anticipated benefits of its strategic activities and other risks and uncertainties included under the heading "Risk Factors" in its most recent Annual Report on Form 10-K, as updated by its subsequent filings with the SEC, all of which are available on the Company's investor relations website at http://www.lemaitre.com and on the SEC's website at http://www.sec.gov . Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.
For information contact: David B. Roberts President LeMaitre Vascular, Inc. 781-425-1693
